Inventor · disambiguated record
Alessandro Moretta
Also filed as: MORETTA ALESSANDRO
21 granted patents·10 pending applications·336 citations·filing 2000–2018
96Inventor score
Top patents by PatentIndex Score
31 records- 0195US8119775B2Human anti-KIR antibodiesMORETTA ALESSANDRO·Filed 2008·Granted Feb 21, 2012·68 cites·20 claims
- 0293US9447185B2Compositions and methods for treating proliferative disordersROMAGNE FRANCOIS·Filed 2006·Granted Sep 20, 2016·46 cites·6 claims
- 0393US8993319B2Monoclonal antibodies against NKG2AMORETTA ALESSANDRO·Filed 2005·Granted Mar 31, 2015·31 cites·1 claims
- 0492US10160810B2Monoclonal antibodies against NKG2AINNATE PHARMA SA·Filed 2015·Granted Dec 25, 2018·14 cites·5 claims
- 0591US8981065B2Human anti-KIR antibodiesNOVO NORDISK AS —NOVO ALLE·Filed 2013·Granted Mar 17, 2015·25 cites·18 claims
- 0689US8637258B2Compositions and methods for regulating NK cell activityPADKJAER SOREN BERG·Filed 2010·Granted Jan 28, 2014·23 cites·14 claims
- 0789US8614307B2Nucleic acids encoding human anti-kir antibodiesMORETTA ALESSANDRO·Filed 2012·Granted Dec 24, 2013·15 cites·13 claims
- 0888US9828427B2Anti-KIR3D antibodiesINNATE PHARMA·Filed 2015·Granted Nov 28, 2017·9 cites·7 claims
- 0988US8133485B2Bi-specific complexes for targeting cells involved in allergic-type reactions, compositions and uses thereofLEVI-SCHAFFER FRANCESCA·Filed 2005·Granted Mar 13, 2012·35 cites·9 claims
- 1086US7517966B2Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the sameINNATE PHARMA SAS·Filed 2005·Granted Apr 14, 2009·9 cites·9 claims
- 1185US7732131B2Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptorINNATE PHARMA SA·Filed 2005·Granted Jun 8, 2010·13 cites·1 claims
- 1285US6979546B2Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the sameINNATE PHARMA SAS·Filed 2002·Granted Dec 27, 2005·23 cites·11 claims
- 1380US9181341B2Anti-KIR3D antibodiesANFOSSI NICOLAS·Filed 2010·Granted Nov 10, 2015·9 cites·11 claims
- 1476US9902936B2PAN-KIR2DL NK-receptor antibodies and their use in diagnostics and therapyMORETTA ALESSANDRO·Filed 2004·Granted Feb 27, 2018·9 cites·31 claims
- 1576US7279291B2Polypeptides having a triggering NK activity and biological applicationsUNIV GENOVA·Filed 2006·Granted Oct 9, 2007·2 cites·5 claims
- 1673US8465931B2Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptorMORETTA ALESSANDRO·Filed 2010·Granted Jun 18, 2013·3 cites·15 claims
- 1771US2010015153A1Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells and Antibodies That Identify the SameINNATE PHARMA SA·Filed 2009·Application pending·0 cites
- 1867US2008248045A1Polypeptides having a triggering nk activity and biological applicationsINNATE PHARMA SA·Filed 2007·Application pending·0 cites
- 1960US7074409B2Polypeptides having a triggering NK activity and biological applicationsUNIV GENOVA·Filed 2001·Granted Jul 11, 2006·1 cites·6 claims
- 2060US2007065875A1NTB-A, a surface molecule involved in natural killer cells activityUNIV GENOVA·Filed 2006·Application pending·0 cites
- 2160US2019135938A1Monoclonal antibodies against nkg2aINNATE PHARMA SA·Filed 2018·Application pending·0 cites
- 2259US7138243B2NTB-A, a surface molecule involved in natural killer cells activityUNIV GENOVA·Filed 2002·Granted Nov 21, 2006·1 cites·3 claims
- 2358US2014193430A1Compositions and methods for regulating nk cell activityNOVO NORDISK AS·Filed 2013·Application pending·0 cites
- 2453US2009191213A9Compositions and methods for regulating NK cell activityNOVO NORDISK AS·Filed 2006·Application pending·0 cites
- 2551US11365393B2Compositions and methods for regulating NK cell activityINNATE PHARMA·Filed 2018·Granted Jun 21, 2022·0 cites·20 claims
- 2651US2015344576A1Human anti-kir antibodiesNOVO NORDISK AS NOVO ALLE·Filed 2015·Application pending·0 cites
- 2750US7569666B2Polypeptides associated with activatory receptors and their biological applicationsINST NAT SANTE RECH MED·Filed 2004·Granted Aug 4, 2009·0 cites·14 claims
- 2849US2013315892A1Therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterpart nk cell receptorUNIV GENOVA·Filed 2013·Application pending·0 cites
- 2949US2015191547A1Human anti-kir antibodiesNOVO NORDISK AS NOVO ALLE·Filed 2015·Application pending·0 cites
- 3041US2007231322A1Compositions and Methods for Treating Proliferative Disorders Such as Nk-Type LdglUNIV GENOVA·Filed 2005·Application pending·0 cites
- 3126US7384631B2Methods of diagnosis and treatment by binding p75/AIRM1UNIV GENOVA BIOFISICA·Filed 2000·Granted Jun 10, 2008·0 cites·6 claims
Join the waitlist — get patent alerts
Get an alert when Alessandro Moretta files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →